Hederacoside C

Hederacoside C is a triterpenoid saponin derived primarily from Hedera helix (common ivy) leaves, where it functions as a major bioactive glycoside. It exerts its effects chiefly through inhibition of acetylcholinesterase and modulation of inflammatory signaling pathways, placing it under active preclinical investigation for cognitive and anti-inflammatory applications.

Origin & History

Hederacoside C is a triterpenoid saponin (oleanane-type glycoside) isolated primarily from the leaves of Hedera helix (English ivy) and the stem bark of Kalopanax pictus. This white crystalline compound with molecular formula C₅₉H₉₆O₂₆ is commercially obtained as a purified extract and must be stored under inert atmosphere at 2-8°C due to hygroscopic stability issues.

Historical & Cultural Context

Hederacoside C is an active component in Hedera helix leaf extracts traditionally used in European herbalism for respiratory disorders such as acute respiratory infections and bronchitis. Specific historical context and duration of use are not documented in available sources.

Health Benefits

• Anti-inflammatory activity demonstrated in preclinical studies (evidence quality: preliminary) • Acetylcholinesterase inhibition with IC₅₀ = 31.3 µM, suggesting potential cognitive support (evidence quality: preliminary) • Antimutagenic effects reducing aflatoxin B1-induced mutagenicity by 21-67% at 0.5-5 µg doses in bacterial cultures (evidence quality: preliminary) • Component of Hedera helix extracts used for respiratory conditions like bronchitis (evidence quality: traditional use only) • Potential bioavailability enhancer for other compounds in oral formulations (evidence quality: preliminary)

How It Works

Hederacoside C inhibits the enzyme acetylcholinesterase with an IC₅₀ of 31.3 µM, reducing the hydrolysis of acetylcholine at synaptic junctions and thereby prolonging cholinergic neurotransmission. It also suppresses pro-inflammatory mediator production, likely through downregulation of NF-κB signaling and inhibition of cyclooxygenase-related pathways, though the precise upstream receptor targets remain under investigation. Its antimutagenic activity appears linked to the inhibition of cytochrome P450-mediated bioactivation of aflatoxin B1 into its reactive epoxide form, reducing DNA adduct formation.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Hederacoside C are available in the current research. All evidence comes from preclinical studies including acetylcholinesterase inhibition assays and antimutagenic testing in S. typhimurium cultures, with no PubMed PMIDs identified.

Clinical Summary

The evidence base for hederacoside C consists entirely of in vitro and animal-model studies, with no published randomized controlled trials isolating this compound in human subjects. Antimutagenic activity was quantified in Salmonella-based Ames test assays, where hederacoside C reduced aflatoxin B1-induced mutagenicity by 21–67% depending on concentration. Acetylcholinesterase inhibition was demonstrated in enzyme-based biochemical assays with an IC₅₀ of 31.3 µM, a value considered moderate compared to pharmaceutical inhibitors such as donepezil (IC₅₀ ~0.023 µM). Anti-inflammatory effects have been observed in cell-based models, but translation to clinical outcomes in humans has not been established, and all findings should be considered preliminary.

Nutritional Profile

Hederacoside C is a purified triterpenoid saponin compound (not a whole food or nutritional ingredient), therefore it does not possess a conventional macronutrient or micronutrient profile. Structurally, it is a bidesmosidic oleanolic acid glycoside with molecular formula C₅₉H₉₆O₂₆ and molecular weight of approximately 1221.4 g/mol. It consists of an oleanolic acid aglycone core esterified with a complex sugar chain including glucose, rhamnose, arabinose, and apiose residues. As a saponin, it contains no dietary protein, fat, or fiber in the nutritional sense. Bioactive compound concentration in dried Hedera helix (ivy) leaf extract typically ranges from 0.5–5% total hederasaponin content, with hederacoside C representing a significant fraction alongside hederacoside B and α-hederin. Oral bioavailability is considered low for intact saponin form due to poor gastrointestinal absorption; metabolic conversion to the active monodesmosidic form α-hederin via intestinal hydrolysis of the terminal sugar is believed to be responsible for primary biological activity in vivo. No vitamins, dietary minerals, or fiber content are inherently associated with this isolated compound. Standardized ivy leaf dry extracts (e.g., EA 575) are typically normalized to 5–7.5 mg hederacoside C per dose in clinical phytomedicine formulations.

Preparation & Dosage

No clinically studied dosage ranges for Hederacoside C in humans are available. The compound has been used in research formulations with DMSO master liquids diluted in PEG300, Tween 80, or corn oil, but human dosing data is not established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other saponins, respiratory botanicals, acetylcholinesterase inhibitors, anti-inflammatory compounds, bioavailability enhancers

Safety & Interactions

Hederacoside C has not been evaluated in dedicated human safety or toxicology trials, making a complete adverse effect profile unavailable. As a constituent of Hedera helix preparations, it may contribute to reported side effects of ivy leaf extracts including nausea, vomiting, and allergic skin reactions, particularly in individuals with sensitivities to Araliaceae family plants. Its acetylcholinesterase-inhibiting activity raises a theoretical interaction risk with cholinergic drugs such as donepezil, rivastigmine, or anticholinergic medications, potentially altering their pharmacodynamic effects. Use during pregnancy and lactation is not recommended due to the absence of safety data, and individuals with liver conditions should exercise caution given limited metabolic characterization.